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Abstract
Background: Schizophrenia is among the most burdensome and costly illnesses worldwide. To estimate the cost
of schizophrenia in France, a longitudinal study was carried out between 1998 and 2002. The main objective of this
study was to describe and update the cost of schizophrenia in a longitudinal, representative sample of French
patients. The second objective was to identify cost drivers in the treatment of schizophrenia.
Methods: Based on a cohort of 288 French schizophrenic patients during 2 years of prospective follow-up, this
study collected clinical, patient reported outcomes, quality of life, functioning, patient management, care giver
involvement and resource utilisation data every 6 months. For each service, information was collected on the type
of service, the frequency of attendance and type of intervention provided to the patient. Unit costs were based
on available French databases. Mean service use and costs over the five time points were estimated using
between-effects regression models.
Results: In the total sample of 288 patients aged 18-64 years, the mean total cost (€ 3 534) was mainly accounted
for by the cost of inpatient treatment (€ 1 390) and day care (€ 1 331). The estimate of the annual cost for direct
medical health care for all French schizophrenic patients was € 1 581 million, including € 621 million for inpatient
treatment and € 595 million for day care (77%). The costs for medication accounted for 16.1% of total annual costs.
The remaining costs (6.9%) included visits to psychiatrists, general practitioners, other physicians and psychologists.
The direct resource allocation showed inpatient treatment as the main direct cost. Unemployment was identified as
a major indirect cost of schizophrenia treatment. Positive and depressive schizophrenia symptoms at baseline and
relapse occurrence during the follow-up period were associated with a higher cost of treatment. Health satisfaction
or negative symptoms of schizophrenia at baseline were associated with lower costs.
Conclusion: Several cost drivers were identified. Based on the results obtained in France, we suggest further
analysis of mechanisms that influence the service-specific costs for schizophrenia in other areas of the world.
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Schizophrenia, which is a psychiatric disease, is asso-
ciated with significant and long-lasting health, social and
financial burden, not only for patients but also for fam-
ilies, other caregivers and the wider society. Although
the lifetime prevalence has not increased (estimated at
0.5% in a recent systematic review [1]), schizophrenia
remains among the most burdensome and costly ill-
nesses worldwide. Considerable progress has been made
during the last 10 years in the treatment of schizophre-
nia. Patients with schizophrenia, given the severity of the
disorder, usually require long-term health care. Though
the economic costs vary from country to country, all the
cost-of-illness estimates highlight the heavy societal bur-
den of schizophrenia [2].
In a cross-sectional study, Rouillon et al. [3] estimated
the direct and indirect annual (in 1992) cost of medical
management of schizophrenia in France to be Fr 12.4
billion ($US 2.34 billion) and Fr 5.2 billion ($US 0.97 bil-
lion), respectively.
The main objective of this study was to describe and
update the cost of schizophrenia using a longitudinal,
representative sample of French schizophrenic patients.
The second objective was to identify cost drivers in
schizophrenia treatment.
Methods
Study design
The data are from the European Schizophrenia Cohort
(EuroSC), conducted in the UK, France, and Germany.
A detailed description of the European Schizophrenia
Cohort has been published earlier [4]. It is a naturalis-
tic, 2-year follow-up of a schizophrenic patient cohort
conducted in Islington and Leicestershire (UK), in
Lille, Lyon and Marseille (France), and in Hemer, Heil-
bronn, Altenburg and Leipzig (Germany). The main
objective of this cohort was to identify and describe
the types of treatment and methods of care for people
with schizophrenia and to correlate these with clinical
outcomes, states of health, and quality of life. This
project was conducted in accordance with the Declar-
ation of Helsinki and French Good Clinical Practices
[5,6]. The study protocol was approved by the Institu-
tion Review Board or the Ethic Committee responsible
for each participating hospital or institution (Camden
& Islington Community Mental Health NHS Trust
Ethics Committee and Leicester University Committee
for Research Ethics for all UK sites, Ethics Committee
of the University of Leipzig for Germany, and Ethics
Committee of the University of Aix-Marseille 2 for
France). Written informed consent was obtained from
each participant after the study details had been fully
explained.
Subjects
In France, mental health care is driven by a law defin-
ing 800 catchment areas (sectors). Each sector has
around 70 000 inhabitants. As resources are unequally
allocated between sectors, the strategy was to integrate
ten adjacent sectors into a single sampling area. Three
such integrated areas were selected. They were located
in northern France (Lille), central France (Lyon and
Clermont-Ferrand) and southern France (Marseille and
Toulon). Each of these areas covered an urban centre
of approximately one million inhabitants living in a
city or in medium-sized towns.
Sampling was achieved by establishing a list of all
mental patients in the areas, using information from the
mental health services, and then sampling at random
from those patients that were identified. Participants
were selected to provide a representative sample of the
patients treated in secondary psychiatric services in each
catchment area. Roofless mental patients were excluded
from the study, as well as people who had been hospita-
lised for the previous 12 months or were planning to
move out of the area. If the participant withdrew con-
sent at any time or if the participant was lost to follow-
up, data collected up to this point were used in the
analysis.
Assessments
At baseline, the Structured Clinical Interview for DSM-
IV (SCID) [7] was used to establish the diagnosis. The
SCID, administered by a clinician, is a record of the
presence or absence of each of the symptoms and disor-
ders being considered for the current episode (past
month) and lifetime occurrence. Socio-demographic
characteristics and the previous course of the illness
were assessed with the Past History and Sociodemo-
graphic Description Schedule (PHSD) [8,9]. The PHSD
was adapted for use in the study. The instrument was
used in the WHO Collaborative Study on the Assess-
ment and Reduction of Psychiatric Disability, and our
adaptation was based on the third draft from 1977.
Clinical assessment of each patient was made by an
external professional. Each assessor was trained for
instruments used in the questionnaire. Schizophrenic
symptomatology was assessed by means of the Positive
and Negative Syndrome Scale (PANSS) [10,11]. Inter-
rater reliability was reported as adequate or good [12].
Depression was measured using the Calgary Depression
Scale for Schizophrenia (CDSS) [13]. The scale is com-
posed of nine questions, rated on a four-point scale. A
global score was obtained by adding the values for each
item [14]. For the assessment of subjective quality of life,
Lehman’s Quality of Life Interview (QoLI) [15] was used.
This measure is comprised of eight domains: living situ-
ation (three items), daily activities (four items), family
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items), legal and safety issues (three items), health (three
items), and work (three items). The answers are
recorded on a seven-point Likert scale anchored by
1=‘terrible’ and 7=‘delighted’. Item scores for each do-
main were combined into a single measure by calculat-
ing the mean item score.
Information about the use of services during the six-
month period preceding each assessment was collected
by means of the Malin System [16]. The system covered
hospital-based services, day clinic activities, outpatient
physician and psychological services, and medications
used by the patient. For each service, information was
collected on the type of service, the frequency of attend-
ance and type of intervention provided to the patient.
Unit cost estimates
Health care costs
Unit costs for outpatient visits were based on the Tarif
Conventionnel, which is a national database for health
information [17]. Unit costs for inpatient and day clinic
treatment were based on a tariff per hospital day fixed
by the regional health law and given by expert informa-
tion from the Ministry of Health in France. In French
psychiatric hospital financing, real costs, such as Diagno-
sis Related Group rates for a general hospital, are not
available. Medication prices were taken from an internet
source for reimbursable medication based on actual
prices [18]. This database was accessed online in Octo-
ber 2007. All other cost estimates are based on data
sources for the years 1999 and 2000.
Cost of lost productivity
A large part of the global economic impact of schizo-
phrenia stems from the difficulties encountered by
patients in finding and keeping paid employment. The
most important feature of indirect costs is the loss of
productivity because of patient morbidity and mortality
(i.e., loss of ability to work) [2].
Here, we assumed that unemployment in patients of
working age was the main indirect cost. The monetary
value of lost productivity was estimated according to the
human capital method [19]. The number of unemployed
individuals was combined with an average gross annual
pay of € 21 492 (for full-time employees during the tax
year 2007 according to Institut National de la Statistique
et des Etudes Economiques (INSEE) data) [20].
Statistical analysis
Mean service use and costs over the five time points
were estimated using between-effects regression models
for every type of resource use surveyed; the temporal
order of the repetitions was not taken into account. The
Weighted Least Squares approach allowed us to make
sure that patients with more time points were weighted
higher than those with fewer time points (considering
their data are less informative/valid). This procedure
took into account the fact that a greater number of com-
pleted follow-ups per respondent implied higher validity
of the estimated mean costs. The model is derived from
a random effects model:
yit ¼ α þ xitβ þ νi þ εit
for i=1,...,n ,and for each i, t=1,...,T iof which Ti
occasions are actually observed. It is defined as:
  yi ¼ α þ   xiβ þ νi þ  εi
where   yi ¼
XTi
t¼1yit=Ti and   xi is defined similarly.
As the number of observations (Ti) is different for
each patient, WLS (weighted least squares) were adopted
for estimation, and Ti served as an analytic weight [21].
Since the data were highly right-skewed, non-parametric
bootstrapping with 4 000 replications was applied. The
analyses were carried out using STATA 10 [22].
Results
Overall, 288 patients aged 18-64 years were recruited for
the study. Sample attrition resulted in 223 participants
taking part in the second interview, 196 in the third, 173
in the fourth, and 138 in the final interview.
Socio-demographic and clinical characteristics
As shown in Table 1, the sample consisted of mostly sin-
gle (72%), male patients (69.7%), with a mean age of
39.6 years. Their mean number of years of education
was 10 years, and 88.5% were unemployed. On average,
the patients had been hospitalised six times before inclu-
sion in the study. Overall, 17.4% of patients relapsed
during the two-year follow-up period.
Service use, medication, and associated costs
In Table 2, the consumption of different services and
associated costs are presented for the total sample and
for the subsample of service users, i.e., those patients
who had used a specific service during the six months
preceding the interview.
In the total sample, the mean estimate of days spent
at a day clinic was almost twice as high as the mean
estimate of days spent in inpatient treatment. This
trend was also noted among service users. In the total
sample, visits to psychiatrists were the most numerous,
followed by General Practitioners (GPs), other physi-
cians and psychologists. Conditional upon the occur-
rence of at least one visit to a given category of health
care professionals, psychologists were the most fre-
quently visited.
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(€ 3 534) was accounted for by the cost of inpatient treat-
ment (€ 1 390) and day care (€ 1 331). The costs for
medication ranked third (€ 570) followed by the cost for
psychiatrist visits (€ 165). The total cost for the
subsample of users of health services was similarly high
because it was comprised of all patients used at least one
service within the preceding six months, that is, almost
the complete sample. The difference between the costs of
inpatient treatment and day care on one hand and the
other services on the other hand is even more
pronounced.
The prevalence of schizophrenia in France in 2005 was
estimated at 0.5% of the general population aged 15 years
or older [23]. This estimate is close to the total preva-
lence of 0.6% reported in older studies [24]. Based on
this estimate, we extrapolated from our sample the an-
nual cost for direct medical health care for all schizo-
phrenic patients in the country. This yielded € 621
million for inpatient treatment and € 595 million for day
care, which amounts to 77.0% of the total annual direct
cost (€ 1 581 million). The costs for medication (€ 255
million) accounted for 16.1% of total annual direct costs.
The rest (6.9%) included visits to psychiatrists (€ 74 mil-
lion), GPs (€ 11 million), other physicians (€ 12 million)
and psychologists (€ 10 million).
Cost of lost productivity
In this sample, the indirect cost linked to productivity
loss for unemployed patients of working age was esti-
mated (n=195 patients unemployed throughout).
Given the schizophrenia prevalence in France, the
annual indirect cost was extrapolated from the sample
for all schizophrenic patients in the country; the esti-
mate of the annual indirect cost of schizophrenia
linked to productivity loss in France yielded € 2 214
million.
Correlates of costs of service use and medication
Table 3 presents the estimates as found by the statis-
tical analysis: the association of resource use costs and
medication costs with socio-demographic characteris-
tics and clinical aspects was examined by means of a
between-regression model. Twenty-two percent of the
variance of the total cost could be explained by the
model.
We found that costs for day care were lower among
employed patients. The higher the positive schizophrenia
symptoms were at baseline, the higher the costs were for
inpatient treatment during the observation period. While
negative symptoms of schizophrenia were associated
with lower costs for GPs and other physicians, depres-
sive symptoms were associated with higher costs for
GPs. Social and occupational functioning at baseline was
unrelated to costs. There was an inverse relationship be-
tween satisfaction with living situation and costs for psy-
chiatrists. Satisfaction with social relations was positively
associated with total cost. The more satisfied patients
were with their financial situation, the higher their
Table 1 Baseline socio-demographic and clinical
characteristics of the sample (N=288)
Variable Result
Gender - N (%)
Male 200 (69.7%)
Female 87 (30.3%)
Age - mean (SD) 39.6 (10.3)
Age categories - N (%)
18-30 62 (21.5%)
31-50 181 (62.9%)
51-65 45 (15.6%)
Years of education - mean (SD) 10.1 (3.0)
Education categories (years of education) - N (%)
0-9 120 (42.4%)
10-12 116 (41.0%)
13-> 47 (16.6%)
Employment - N (%)
Employed 33 (11.5%)
Marital status - N (%)
Single 206 (71.8%)
Other 81 (28.2%)
Living situation - N (%)
Alone 103 (36.0%)
Other 183 (64.0%)
Number of hospitalisations - mean (SD) 6.4 (5.9)
PANSS positive categories - N (%)
0-18 210 (73.4%)
19-31 76 (26.6%)
PANSS negative categories - N (%)
0-25 217 (75.9%)
26-43 69 (24.1%)
CDSS - mean (SD) 3.6 (4.1)
QoLI: Living situation - mean (SD) 4.6 (1.5)
QoLI: Daily activities and functioning - mean (SD) 4.8 (1.1)
QoLI: Family - mean (SD) 4.5 (1.6)
QoLI: Social relations - mean (SD) 4.9 (1.2)
QoLI: Finances - mean (SD) 4.2 (1.5)
QoLI: Legal and safety issues - mean (SD) 4.9 (1.4)
QoLI: Health - mean (SD) 4.6 (1.6)
Relapse - N (%) 50 (17.4%)
PANSS=Positive And Negative Syndrome Scale, CDSS=Calgary Depression
Scale for Schizophrenia, QoLI=Quality of Life Instrument (QoLI).
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patients were satisfied with their health, the lower the
costs were for other physicians. There was no relation-
ship between the number of previous hospitalisations
and cost. Patients who relapsed during the follow-up
period had higher costs for inpatient treatment and
medication, as well as total costs, than those without
relapse.
Discussion
The cost of schizophrenia has been estimated in a num-
ber of studies. The main common result in all of these
studies is the elevated hospitalisation cost, which heavily
impacts direct medical mental health costs [2].
The main objective of this study was to describe and
update resource allocation for French schizophrenic
patients, based on the EuroSC cohort, which is a
Table 2 Estimated service use and mean costs in total sample and among health service users during a six-month
period
Total sample (n=288) Users of health services
Mean service use (SE) Mean costs (SE) in euros n Mean service use (SE) Mean costs (SE) in euros
Inpatient days 5.72 (0.83) 1390 (203) 54 39.10 (3.89) 9499 (945)
Day clinic days 10.96 (1.55) 1331 (188) 49 62.35 (4.73) 7573 (575)
Psychiatrist visits 5.04 (0.23) 165 (8) 229 6.05 (0.24) 199 (8)
Psychologist visits 0.60 (0.15) 23 (6) 11 11.47 (1.67) 439 (64)
GP visits 1.50 (0.23) 25(4) 39 4.89 (0.63) 82 (11)
Other physician visits 1.32 (0.29) 29 (6) 16 8.46 (1.45) 186 (32)
Medication - 570 (29) 280 - 579 (29)
Total - 3534 (283) 280 - 3552 (282)
The consumption of services is presented for the total sample and for the subsample of service users, i.e., for those patients who have used a specific service.
Table 3 Correlates of direct medical mental health care costs of schizophrenia
Variable Inpatient Day clinic GP Psychiatrist Psychologist Other physician Medication Total
Gender (Female) -760.49 529.15 -1.47 5.95 -4.33 -10.57 -1.45 -243.21
Age -26.41 -18.43 0.39 -1.69 -0.19 0.84 -8.32* -53.83
Years of education 113.54 -9.19 0.03 -2.59 1.71 -1.73 14.28 116.04
Employment (Employed) -87.38 -1286.58* 13.92 19.03 5.81 -30.00 -16.71 -1348.48
Marital status (Single) 206.07 811.70 18.23 7.34 15.52 -2.88 64.97 1120.95
Living arrangement (Living alone) 762.76 -189.86 4.13 -5.10 21.18 -14.46 111.80 690.44
PANSS positive 141.24* -66.16 0.03 2.75 0.38 2.60 3..88 84.72
PANSS negative 80.96 35.26 -2.54* -1.00 1.10 -2.88* 8.69 119.58
CDSS 59.16 64.12 7.44 4.93 5.55 8.49* 24.46 174.15
SOFAS 19.33 -19.66 -0.62 -0.10 0.57 0.69 3.80 4.01
Living situation 264.66 184.65 -6.95 -24.89*** -4.42 -10.94 5.19 407.29
Daily activities and functioning -605.17 -129.63 28.56 19.75 26.93 15.25 -24.63 -668.94
Family 129.74 79.53 -7.51 4.19 -3.70 -2.07 -5.37 205.56
Social relations 462.32 472.71 -4.65 3.28 -12.53 4.13 -27.85 897.41*
Finances 264.00 398.99* -8.12 -2.78 10.11 3.42 26.74 692.37*
Legal and safety issues -195.87 165.61 12.92 16.06 6.62 15.35 60.14 80.83
Health -243.15 7.58 -5.60 -4.41 1.92 -17.80* -3.30 -264.76
Hospitalisations -3.61 77.02 -0.85 -0.96 -1.43 2.56 -2.45 70.28
Relapse 8443.55*** -921.47 -27.80 75.01 34.36 -68.31 619.88** 8155.22**
Constant 1020.91 737.16 12.29 156.05*** 12.50 51.61** 444.48*** 2435.01***
N 245 245 245 245 245 245 245 245
R² between 0.20 0.14 0.24 0.13 0.07 0.20 0.20 0.22
PANSS=Positive And Negative Syndrome Scale, CDSS=Calgary Depression Scale for Schizophrenia, QoLI=Quality of Life Instrument (QoLI).
*p≤0.05; ** p≤0.01; *** p≤0.001.
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phrenic patients. Given the course of the disease, schizo-
phrenic patients’ care is usually managed by their
“psychiatric sectors”, French mental health catchment
areas. The patient selection process allowed us to obtain
a random sample of this population. Moreover, this sam-
ple was followed prospectively during a two-year period.
Thus, the resource utilisation collection was standar-
dised and prospective.
In France, in 1992, Rouillon et al. [3] were the first to
evaluate the cost of treatment in medical and social
terms. Because of the different methodology used, a dir-
ect comparison with this study is not possible. In the
previous study, a mail survey was conducted among all
practising psychiatrists in France, who were requested to
provide information on the patients they had most re-
cently seen or examined. Unfortunately, the response
rate (8%) was very low, raising questions about the rep-
resentativeness of the sample. By contrast, in the present
study, patients were randomly drawn from three defined
catchment areas located in Northern, Central and
Southern France. While in the previous study the diag-
nosis was made by the treating psychiatrists, in the
present study, it was based on a structured interview
(SCID) conducted by trained interviewers. In the previ-
ous study, retrospective data on resource consumption
were obtained from case files, while in the present study,
patients were interviewed 5 times at 6 month intervals.
In the previous study, the cost of lost employment was
assessed using social assistance allowances, while in the
present study, information on employment status pro-
vided by patients served as the basis for this assessment.
In contrast to the previous study, costs for psychologists,
GPs and non-psychiatric specialists have also been
included, while costs for intermediate services other
than day clinics have not been included.
As usual, the financial costs of schizophrenia to society
can be divided into direct and indirect costs. In the
study by Rouillon, direct costs included treatment pro-
vided in inpatient services (55%), intermediate facilities
(30%), outpatient visits (9.5%) and medication costs
(5.5%).
In the present study, the breakdown of direct costs
was different. The proportions of costs related to in-
patient care, day clinic or outpatient care were lower
(39.3%, 37.6% and 6.8%, respectively) compared to the
Rouillon study, and medication costs accounted for a
larger part of the total costs (16.1%).
Even though the present inpatient admission cost is
slightly lower than that in the Rouillon study (from 85%
to 77.0%), it remained the single largest contributor to
French direct costs of treating schizophrenia. The de-
crease in inpatient admission costs may be attributed to
the cost being reported as day clinic hospitalisation.
The contribution of drug costs to the total cost of
treatment seems to have increased in France (from 5.5%
to 16.1%). In the study by Knapp et al. [2], the use of
atypicals had pushed up drugs’ cost contribution to the
total cost, partly because of their higher prices and partly
because of potential reduction in inpatient stays, thus
potentially reducing the total cost.
In another study by Salize et al. (2009) [25], as part of
a randomised controlled trial (RCT) in six European
sites, the direct mental health care cost for 422 patients
with schizophrenia was analysed according to how total
and medication costs differed across sites and which
variables were likely to predict total or service-specific
costs. A difference in the basic study design does not
allow direct comparison. In the RCT, although samples
were homogeneous, large inter-site cost differences were
found (annual means ranging from € 2 958 in Spain up
to € 36 978 in Switzerland). In this study, the annual
cost was extrapolated to be € 3 796 million. In the RCT,
psychopharmacologic costs were much more constant
across sites than costs for other services. Total costs
were associated more with regional or socio-
demographic characteristics than with disorder-related
parameters. By contrast, in the present study, costs were
virtually unrelated to socio-demographic characteristics.
The RCT confirmed remarkable differences in direct
costs of patients with schizophrenia across Europe.
However, the relative stability of medication costs sug-
gested a need to analyse mechanisms that influenced
service-specific costs for schizophrenia. By contrast, in
the present study, we found the increase in medication
costs in France to be higher and in the range of 5.5% to
16.1%. We also identified several mechanisms, such as
depression at baseline, satisfaction with living conditions,
social relations, cost of psychiatrists, and financial condi-
tion, that affecting the cost of treatment.
In the present study, the indirect cost linked to prod-
uctivity loss for unemployed patients of working age was
estimated as a heavy cost, even if the estimation was
only reasonably accurate.
Several cost drivers were identified: positive or depres-
sive symptoms of schizophrenia as well as relapse of
symptoms during the follow-up period predicted higher
costs; satisfaction with health or negative symptoms of
schizophrenia at baseline was linked with lower costs.
Socio-demographic characteristics, social and occupa-
tional functioning at baseline and number of previous
hospitalisations were unrelated to costs. This finding is
consistent with the results from the study by Knapp [2].
Our study has several limitations.
First, this study focuses on treatment and health care
costs. Although cost of lost productivity through un-
employment is included in the analysis, all other indirect
costs are ignored. Costs to patients may also include
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tality (whilst premature mortality may be attributable in
part to the risks of suicide, it may also be the result of
other factors, such as poor living conditions, poor nutri-
tion, or decreased access to healthcare services), costs of
informal caregivers (the costs incurred by the family
members of the patient incorporate several components,
including personal suffering and sometimes loss of prod-
uctivity that should be assessed as well), criminal justice
system costs, social welfare costs, and private alternative
therapy costs and may also include intangible costs.
Second, there was a high rate of attrition in the sam-
ple. Although this was handled in our statistical analysis,
sensitivity analysis using several imputation techniques
could provide a better understanding of the variability of
the estimates.
Third, comorbidities were not taken into account in
this analysis. There is evidence associating other condi-
tions with schizophrenia that also require treatment. For
example, people with schizophrenia are more likely to
suffer from diabetes and cardiovascular disorders. Eco-
nomic costs incurred by managing these comorbidities
are and will continue to represent a considerable burden
on health services [26].
Finally, although large efforts have been made to ob-
tain a representative sample of the French schizophrenic
population, we recognise that our results should be
taken with caution because of the sample size.
Further research is needed on how to evaluate indirect
costs and caregiver costs. Sample attrition in schizophre-
nia cohorts is common and appropriate techniques
should be explored. Finally, comorbid illness (in general
and mental health) should be included in further
research.
Conclusions
This study described resource allocation in a longitu-
dinal, representative sample of French schizophrenic
patients. Cost drivers were also identified.
In the sample of 288 French schizophrenic patients
aged 18-64 years, the direct resource allocation showed
that inpatient admissions remained the single largest
contributor to French direct costs of treating schizo-
phrenia, with day clinic hospitalisation and an increase
in the cost of medications included as a part of inpatient
admissions. Unemployment was identified as a major in-
direct cost of schizophrenia treatment.
Positive and depressive schizophrenia symptoms pre-
dicted a higher cost of treatment. Health satisfaction or
negative symptoms of schizophrenia were linked with
lower costs.
We found that schizophrenia is an economic burden
in France. Based on the results obtained in France, we
suggest further analysis of mechanisms that influence
the service-specific costs for schizophrenia in other areas
of the world.
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